EMIT IMAGING’s CFT technology is a 3D imaging technique that provides high-resolution, high-sensitivity imaging of biological samples to offer key insights into the behaviour of drugs and proteins
The CFT technology of EMIT IMAGING provides high-resolution, high-sensitivity imaging of biological samples. (Credit: National Cancer Institute on Unsplash)
EMIT IMAGING has announced a project with the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (MIT) to advance the former’s 3D imaging technology.
The US-based EMIT IMAGING is a provider of cryo-fluorescence tomography (CFT) imaging technology.
Its CFT technology is a 3D imaging technique that enables high-resolution, high-sensitivity imaging of biological samples to offer key insights into the behaviour of drugs and proteins.
The upcoming project will use Koch Institute’s research-based experiences into workflow and method improvements of CFT. This will enable greater accuracy and efficiency in studying cancer and other diseases, said EMIT IMAGING.
Koch Institute preclinical imaging and testing facility scientific director Virginia Spanoudaki said: “Cryo-Fluorescence Tomography elegantly fits into the preclinical evaluation lifecycle by providing a full-body view of a wide range of fluorescent signatures of disease and therapy right at the selected endpoints.
“Here at MIT, we are working to fully utilise the immense potential of the technology by co-registering it with in vivo modalities and using it as a bridge between in vivo imaging and other spatial and high-throughput assays.”
Through the partnership, EMIT IMAGING plans to launch its technology for cancer research, thereby improving the biological and drug research process.
EMIT IMAGING CEO Matthew Silva said: “We are thrilled to be working with the Koch Institute for Integrative Cancer Research, a world-renowned leader in cancer research.
“Their expertise and experience will undoubtedly help us improve our cryo-fluorescence tomography technology, allowing us to provide more accurate and efficient results to researchers and our customers.”
EMIT IMAGING said that the work with the Koch Institute demonstrates the significance of collaboration in the field of scientific research and medical imaging for advancing research tools and methods.
The imaging firm’s Xerra platform is designed to offer high-sensitivity and high-resolution 3D images of biological samples.
According to EMIT IMAGING, Xerra technology is used by biotechnology, pharmaceutical, and academic researchers around the world to advance scientific and medical research.